Discovering the Therapeutic Potential of Mounjaro® (tirzepatide): A Case Report

Case Report: Overview: GIP/GLP- 1 receptor agonists had a profound effect on the treatment of type 2 diabetes, however it has also been a turning point in the management of weight loss and cardiovascular health. While there are known FDA-approved indications for this novel drug class, there are far more potential therapeutic outcomes and benefits to be discovered in post-marketing surveillance. This patient case aims to evaluate the impact Mounjaro® (tirzepatide) has on weight reduction, glycemic control, and reduction of congestive heart failure prevalence. Purpose: The purpose of this research is to evaluate the effects of Mounjaro ® (tirzepatide) on a patient's cardiac health, glycemic control, and weight reduction. By understanding these outcomes, we aim to inform clinical practices and enhance patient care within our community. Summary: JK is a 58 y.o male with a past medical history of hypertension, type 2 diabetes mellitus & obesity who presents to the PCOM family clinic with difficulty achieving weight loss and poor management of blood glucose despite being treated with Lantus and Novolog which have been gradually increased, requiring significantly higher insulin dosages to reduce hyperglycemia. He was then initiated on Mounjaro® (tirzepatide) to help achieve his goals. Mounjaro Doses Initiated: February 2024: 2.5mg weekly; March 2024, increased to 5mg weekly; May 2024 increased to 7.5mg weekly. Patient prefers to continue current Mounjaro dosage; dosing range available up to 15mg weekly. Results: JK has had a 50 pound weight loss since initiating Mounjaro (April 2024: 456 lbs, Sep 2024: 406 lbs). He had a 1.7% deduction in A1C (nov 2023 7.6%, Aug 2024 5.9%) and his blood pressure has decreased from 172/73 (may 2024) to 118/66 (aug 2024). His insulin regimen of Lantus + Novolog has been reduced and improved in sensitivity. Discussion: Mounjaro ® (tirzepatide) is a powerful therapeutic agent that supports glycemic control, weight loss, reduced insulin requirements, as well as improved cardiovascular metabolic parameters. Mounjaro® is currently being evaluated in SURPASS-CVOT study regarding reduction in the risk of MACE in patients with T2DM. CHF is a highly prevalent chronic disease with significant morbidity and mortality. Unfortunately, it is well-known that a CHF diagnosis usually occurs in patients with concurrent conditions like T2DM, HTN, and obesity, as well as other risk factors. GIP/GLP- 1 receptor agonists may offer a possible therapeutic opportunity to prevent CHF by addressing the underlying risk factors. While being prescribed for FDA-approved indications, GIP/GLP- 1 receptor agonists have made a profound impact involving our community health. Reducing obesity rates can decrease the prevalence of chronic diseases such as T2DM and cardiovascular diseases. Unfortunately, due to its high demand and limited supply, many people are turning to illegal online pharmacies and businesses that are selling unsafe and possibly contaminated versions of these prescriptions. Pharmacists can aid in providing valuable counseling on medication assistance programs, potential side effects, affordable alternatives, and navigating the distribution issues that patients face within the existing, complicated health care system. Pharmacist can also provide medication management to empirically avoid hypoglycemia, closely monitor patients for safety and efficacy, and prevent future hospitalizations. Conclusion: Mounjaro® represents a significant advancement in the treatment of T2DM and obesity, with compelling evidence supporting its efficacy in improving glycemic control and cardiovascular health as well as promoting weight loss. The individual success of this patient case highlights the transformative potential of this therapeutic class. Additional studies are warranted to determine the correlation between GIP/GLP- 1 receptor use and prevalence of CHF diagnoses. The broader community benefits of weight loss, combined with the essential role of pharmacists in clinical settings, underscore the need for integrated healthcare approaches to enhance patient outcomes and public health. Future efforts should focus on increasing the availability of pharmacists in clinical environments to ensure comprehensive patient care, effective medication management, and achieving public health goals.